BDX Stock Overview
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Becton, Dickinson and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$219.30 |
| 52 Week High | US$261.00 |
| 52 Week Low | US$213.00 |
| Beta | 0.46 |
| 1 Month Change | -0.77% |
| 3 Month Change | 1.06% |
| 1 Year Change | -7.66% |
| 3 Year Change | 3.74% |
| 5 Year Change | 3.13% |
| Change since IPO | 3.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| BDX | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 0.09% | 0.6% | 1.5% |
| 1Y | -7.7% | 1.1% | 3.5% |
Return vs Industry: BDX underperformed the Austrian Medical Equipment industry which returned -1.8% over the past year.
Return vs Market: BDX underperformed the Austrian Market which returned 2.2% over the past year.
Price Volatility
| BDX volatility | |
|---|---|
| BDX Average Weekly Movement | 1.9% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in AT Market | 5.2% |
| 10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: BDX has not had significant price volatility in the past 3 months.
Volatility Over Time: BDX's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 73,000 | Tom Polen | www.bd.com |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Becton, Dickinson and Company Fundamentals Summary
| BDX fundamental statistics | |
|---|---|
| Market cap | €63.12b |
| Earnings (TTM) | €1.18b |
| Revenue (TTM) | €18.21b |
53.5x
P/E Ratio3.5x
P/S RatioIs BDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDX income statement (TTM) | |
|---|---|
| Revenue | US$19.49b |
| Cost of Revenue | US$10.78b |
| Gross Profit | US$8.72b |
| Other Expenses | US$7.45b |
| Earnings | US$1.27b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 4.38 |
| Gross Margin | 44.72% |
| Net Profit Margin | 6.49% |
| Debt/Equity Ratio | 63.6% |
How did BDX perform over the long term?
See historical performance and comparison